Molecular Predictors in Head and Neck Tumours
Authors:
P. Smilek
Authors place of work:
Klinika otorinolaryngologie a chirurgie hlavy a krku, FN u sv. Anny v Brně a LF MU, Brno
Published in the journal:
Klin Onkol 2010; 23(4): 218-223
Category:
Reviews
Summary
This review summarizes biological markers of head and neck cancer, which have emerged from recent developments in molecular changes during carcinogenesis. These markers could be evaluated in every step that is believed to be necessary for the development of a cancer: acquisition of autonomous proliferative signalling (EGFR), proliferative activity of tumour cells (DNA content, Ki‑ 67, mitotic index), inhibition of growth inhibitory signals (Bcl‑ 2), apoptosis (p53), immortalization (telomerase), angiogenesis (CD34, VEGF) and metastasis (MMP‑ 9, E‑ cadherin, I‑ CAM aj.). Most of these biological markers are at the preclinical research stage. Significant progress has been achieved in the application of targeted therapy in head and neck cancer.
Key words:
head and neck cancer – biological markers – prognosis – targeted therapy
Zdroje
1. Hanahan D, Weinberg RA. The Hallmarks of Cancer. Cell 2000; 100(1): 57– 70.
2. Überall I, Kolář Z. Receptory pro epidermální růstové faktory a jejich význam pro maligní transformaci solidních nádorů. Klin Farmakol Farm 2006; 20; 190– 196.
3. Smilek P. Prognostické a prediktivní parametry dlaždicobuněčných karcinomů vybraných lokalizací hlavy a krku. Habilitační práce. Brno: LF MU 2009.
4. Schartinger VH, Kacani L, Andrle J et al. Pharmacodiagnostic Value of the HER Family in Head and Neck Squamous Cell Carcinoma. ORL J Otorhinolaryngol Relat Spec 2004; 66(1): 21– 26.
5. Ang KK, Berkey BA, Tu X et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 2002; 62(24): 7350– 7356.
6. Temam S, Kawaguchi H, El‑ Naggar AK et al. Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer. J Clin Oncol 2007; 25(16): 2152– 2155.
7. Grandis JR, Melhelm MF, Holding WE et al. Levels of TGF‑alpha and EGF‑ R protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 1998; 90: 824– 832.
8. Myers EN, Suen JY, Myers JN et al. Cancer of the head and neck. 4th ed. Elseviere Science 2003.
9. Bentzen SM, Atasoy BM, Daley FM et al. Epidermal growth factor receptor expression in pretreatment biopsies from head and neck squamous cell carcinoma as a predictive factor for a benefit from accelerated radiation therapy in a randomized controlled trial. J Clin Oncol 2005; 23(24): 5437– 5439.
10. Wells A. Cell Motility in Cancer Invasion and Metastasis. Netherlands: Springer 2006.
11. Hitt R, Ciruelos E, Amador ML et al. Prognostic value of the epidermal growth factor receptor (EGRF) and p53 in advanced head and neck squamous cell carcinoma patients treated with induction chemotherapy. Eur J Cancer 2005; 41(3): 453– 456.
12. Lavertu P, Adelstein DJ, Myles J et al. P53 and Ki‑ 67 as Outcome Predictors for Advanced Squamous Cell Cancers of the Head and Neck Treated with chemoradiotherapy. Laryngoscope 2001; 111: 1878– 1892.
13. Shin DM, Charuruks N, Lippman SM et al. P53 protein accumulation and genomic instability in head and neck multistep tumorigenesis. Cancer Epidemiol Biomarkers Prev 2001; 10(6): 603– 609.
14. Vielba R, Bilbao J, Ispizua A et al. P53 and Cyclin D1 as Prognostic Factors in Squamous Cell Carcinoma of the Larynx. Laryngoscope 2003; 113: 167– 172.
15. Shin DM, Charuruks N, Lippman SM et al. P53 protein accumulation and genomic instability in head and neck multistep tumorigenesis. Cancer Epidemiol Biomarkers Prev 2001; 10: 603– 609.
16. Clayman GL, El‑ Naggar AK, Roth JA et al. In vivo molecular therapy with p53 adenovirus for microscopic residual head and neck squamous carcinoma. Cancer Res 1995; 55(1): 1– 6.
17. Rejthar A, Vojtěšek B. Obecná patologie nádorového růstu. 1. vyd. Praha: Grada 2002.
18. Costa A, Licitra L, Veneroni S et al. Biological markers as indicators of pathological response to primary chemotherapy in oral‑ cavity cancers. Int J Cancer (Pred Oncol) 1998; 79(6): 619– 623.
19. Jäckel MC, Sellmann L, Dorudian MA et al. Prognostic significance of p53/ bcl‑ 2 co‑ expression in patients with laryngeal squamous cell carcinoma. Laryngoscope 2000; 110 (8): 1339– 1345.
20. Lehnerdt GF, Franz P, Bankfalvi A et al. The regulatory BCL2 promoter polymorphism (‑ 938 C > A) is associated with relapse and survival of patiens with oropharyngeal squamous cell carcinoma. Ann Oncol 2009; 20(6): 1094– 1099.
21. Mao L, El‑ Naggar AK, Fan YH et al. Telomerase activity in head and neck squamous cell carcinoma and adjacent tissues. Cancer Res 1996; 56(24): 5600– 5604.
22. El Samny T, El Halaby H, El Fiky L et al. Prognostic value of telomerase and DNA ploidy in laryngeal carcinoma. Eur Arch Otorhinolaryngol 2005; 262(10): 799– 803.
23. Mutirangura A, Supiyaphun P, Trirekepan S et al. Telomerase Activity in Oral Leukoplakia and Nead and Neck Squamous Cell Carcinoma. Cancer Res 1996; 56(15): 3530– 3533.
24. Wright WE, Pereira‑ Smith OM, Shay JW. Reversible cellular senescence: implications for immortalization of normal human diploid fibroblasts. Mol Cell Biol 1989; 9(7): 3088– 3092.
25. Kamijo T, Yokose T, Hasebe T et al. Potential role of microvessel density in predicting radiosensitivity of T1 and T2 stage laryngeal squamous cell carcinoma treated with radiotherapy. Clin Cancer Res 2000; 6(8): 3159– 3165.
26. Shpitzer T, Chaimaoff M, Gal R et al. Tumor angiogenesis as a prognostic factor in early oral tongue cancer. Arch Otolaryngol Head Neck Surg 1996; 122(8): 865– 868.
27. Zätterström UK, Brun E, Willén R et al. Tumor angiogenesis and prognosis in squamous cell carcinoma of the head and neck. Head Neck 1995; 17(4): 312– 318.
28. Dray TG, Hardin NJ, Sofferman RA. Angiogenesis as a prognostic marker in early head and neck cancer. Ann Otol Rhinol Laryngol 1995; 104(9 Pt 1): 724– 729.
29. Lopéz‑ Graniel CM, Tamez de León D et al. Tumor angiogenesis as a prognostic factor in oral cavity carcinomas. J Exp Clin Cancer Res 2001; 20(4): 463– 468.
30. Smith BD, Haffty BG, Sasaki CT. Molecular markers in head and neck squamous cell carcinoma: their biological function and prognostic significance. Ann Otol Rhinol Laryngol 2001; 110(3): 221– 228.
31. Georgolios A, Batistatou A, Manolopoulos L. Role and Expression Patterns of E‑ Cadherin in Head and Neck Squamous Cell Carcinoma (HNSCC). J Exp Clin Cancer Res 2006; 25(1): 5– 14.
32. Do NY, Lim SC, Im TS. Expression of c‑ erbB receptors, MMPs and VEGF in squamous cell carcinoma of the head and neck. Oncol Rep 2004; 12(2): 229– 237.
33. Welkoborski HJ, Hinni M, Dienes HP et al. Predicting recurrence and survival in patients with laryngeal cancer by means of DNA cytometry, tumor front grading, and proliferation markers. Ann Otol Rhinol Laryngol 1995; 104(7): 503– 510.
34. Maga G, Hubscher U. Proliferating cell nuclear antigen (PCNA): a dancer with many partners. J Cell Sci 2003; 116(Pt 16): 3051– 3060.
35. Liu M, Lawson G, Delos M et al. Prognostic value of cell proliferation markers, tumour suppressor proteins and cell adhesion molecules in primary squamous cell carcinoma of the larynx and hypopharynx. Eur Arch Otorhinolaryngol 2003; 260(1): 28– 34.
36. Yip TT, Lau WH, Chan JKC et al. Prognostic Significance of DNA Flow Cytometric Analysis in Patients with nasopharyngeal Carcinoma. Cancer 1998; 83(11): 2284– 2292.
37. Takes RP, Baatenburg de Jong RJ, van Blommestein R et al. DNA ploidy status as a prognostic marker and predictor of lymph node metastasis in laryngeal carcinoma. Ann Otol Rhinol Laryngol 2002; 111(11): 1015– 1020.
38. Das SN, Khare P, Patil A et al. Association of DNA pattern of metastatic lymph node with disease free survival in patients with intraoral squamous cell carcinoma. Indian J Med Res 2005; 122(3): 216– 223.
39. Raybaud‑ Diogène H, Fortin A, Morency R et al. Markers of radioresistance in Squamous Cell Carcinomas of the Head and Neck: A Clinicopathologic and Immunohistochemical Study. J Clin Oncol 1997; 15(3): 1030– 1038.
40. Couture C, Raybaud‑ Diogène H, Tètu B et al. p53 and Ki‑ 67 as markers of radioresistance in head and neck carcinoma. Cancer 2002; 94(3): 713– 722.
41. Plzák J, Betka J, Smetana K jr et al. Galectin‑3 – an emerging prognostic indicator in advanced head and neck carcinoma. Eur J Cancer 2004; 40(15): 2324– 2330.
42. Neuwirthová J, Mechl Z, Smilek P et al. Integrace nových biologických přípravků do léčby spinocelulárních karcinomů hlavy a krku. Remedia 2007; 17(2): 181– 187.
43. Gillison ML. HPV and prognosis for patiens with oropharynx cancer. Eur J Cancer 2009; 45(Suppl 1): 383–385.
Štítky
Paediatric clinical oncology Surgery Clinical oncologyČlánok vyšiel v časopise
Clinical Oncology
2010 Číslo 4
- Metamizole at a Glance and in Practice – Effective Non-Opioid Analgesic for All Ages
- Metamizole vs. Tramadol in Postoperative Analgesia
- Spasmolytic Effect of Metamizole
- Possibilities of Using Metamizole in the Treatment of Acute Primary Headaches
- Current Insights into the Antispasmodic and Analgesic Effects of Metamizole on the Gastrointestinal Tract
Najčítanejšie v tomto čísle
- Merkel Cell Skin Carcinoma
- Metastatic Breast Cancer in 28 Years Old Man
- Bile Duct Malignancies
- Targeted Therapy with an EGFR Tyrosine Kinase Inhibitor in Bronchioloalveolar Carcinoma of the Lung: A Literature Review and a Case Study of Clinically Prompt and Intensive Response to Erlotinib.